BDX's recent acquisition of Critical Care assets from Edwards Lifesciences is poised to enhance its product portfolio and profitability, potentially adding at least $0.36 to annual EPS. Despite current skepticism reflected in its range-bound stock performance, analysts believe BDX's conservative FY25 guidance allows room for positive surprises, especially if it successfully integrates the new assets and improves sales in challenging markets like China. Analysts have set optimistic price targets, with Citi Research upgrading its rating to Buy and a target of $275.
Seems like the connection with the server has been lost. It can be due to poor or broken network. Please hang on while we're trying to reconnect...
Oh snap! Failed to reconnect with the server. This is typically caused by a longer network outage, or if the server has been taken down. You can try to reconnect, but if that does not work, you need to reload the page.
Oh man! The server rejected the attempt to reconnect. The only option now is to reload the page, but be prepared that it won't work, since this is typically caused by a failure on the server.